Abstract：Objective: To explore the evaluation value of peripheral blood microRNA-34b (miR-34b) for targeted therapy effect and prognosis in patients with stage Ⅲb-Ⅳ non-small cell lung cancer (NSCLC). Methods: A total of 104 NSCLC patients who received targeted treatment from January 2020 to January 2022 were selected. According to the efficacy of targeted treatment, they were divided into the effective group (n=40) and ineffective group (n=64). All patients were followed up for one year, and based on the prognosis, they were divided into the survival group (n=32) and death group (n=72). Real-time quantitative PCR was used to detect miR-34b in peripheral blood. The receiver operating characteristic curve (ROC) was employed to analyze the evaluation value of peripheral blood miR-34b expression level for the targeted treatment effect and prognosis of stage Ⅲb-Ⅳ NSCLC patients. Kaplan-Meier survival curve analysis was used to explore the relationship between different peripheral blood miR-34b expression levels and the prognosis of stage Ⅲb-Ⅳ NSCLC patients. Results: The peripheral blood miR-34b expression level in the effective group was higher than that in the ineffective group (P<0.05). The ROC curve showed that the AUC of peripheral blood miR-34b expression level in evaluating the targeted treatment effect of stage Ⅲb-Ⅳ NSCLC patients was 0.856 (P<0.05). The peripheral blood miR-34b expression level in the survival group was higher than that in the death group (P<0.05). The ROC curve showed that the AUC of peripheral blood miR-34b expression level in evaluating the prognosis of stage Ⅲb-Ⅳ NSCLC patients was 0.916 (P<0.05). The Log-rank test showed a statistically significant difference in survival rate between the miR-34b > 2.16 group and miR-34b ≤ 2.16 group (P<0.05). Conclusion: The expression level of peripheral blood miR-34b is associated with the targeted treatment effect and prognosis of stage Ⅲb-Ⅳ NSCLC patients. Detecting the expression level of peripheral blood miR-34b is helpful for evaluating the targeted treatment effect and prognosis.
张亚鹏, 任玉川, 刘昭, 吕晓燕, 李永利. 外周血中miR-34b表达水平对Ⅲb~Ⅳ期NSCLC患者靶向治疗效果及预后的评估价值分析[J]. 河北医学, 2024, 30(1): 45-49.
ZHANG Yapeng, REN Yuchuan, LIU Zhao, et al. Evaluation of the Expression Level of miR-34b in Peripheral Blood for Targeted Treatment Effect and Prognosis in Stage Ⅲb-Ⅳ NSCLC Patients. HeBei Med, 2024, 30(1): 45-49.
[1] 陈靖宇,张欢,夏杨晨,等.老年晚期非小细胞肺癌患者免疫治疗的疗效和安全性[J].肿瘤预防与治疗,2022,35(9):800-811. [2] 丁浩,徐辉,龚晨虎,等.泛素C末端水解酶-L1的表达水平与非小细胞肺癌患者临床病理特征及预后的关系[J].国际检验医学杂志,2023,44(2):166-171. [3] 王伟,金朝晖,范伏元,等.miR-340与Nrf2在非小细胞肺癌患者靶向治疗耐药中的表达及相关性分析[J].肿瘤药学,2021,11(1):87-90. [4] 关英,郭丽云,王千千,等.血清微小RNA-150表达水平与晚期非小细胞肺癌患者行表皮生长因子受体酪氨酸激酶抑制剂治疗效果及预后的关系[J].广西医学,2021,43(22):2660-2664. [5] 苏亚峰,郭石平,廉建红,等.miRNA-34b在非小细胞肺癌组织中的表达及其对A549细胞增殖和侵袭能力的影响[J].肿瘤研究与临床,2022,34(7):507-510. [6] 李国霞,刘向玲.MIC-1、CYFRA21-1、TMB水平与晚期非小细胞肺癌靶向治疗疗效的相关性[J].医学临床研究,2022,39(9):1307-1310+1314. [7] 胡奎,张娴,白彪胜,等.CT影像组学模型预测靶向药物治疗表皮生长因子受体基因突变非小细胞肺癌患者预后[J].中国医学影像技术,2022,38(10):1491-1495. [8] 韩文梅,张文升,袁书堂.DCE-MRI在NSCLC诊断及分子靶向药物治疗效果评估中的应用[J].中国CT和MRI杂志,2021,19(1):1-3. [9] 张珍玉,刘倩倩,王延钰,等.circNFⅨ通过miR-34a调节MET/PI3K/AKT信号通路对非小细胞肺癌细胞增殖、凋亡和上皮间质转化的影响[J].中华肿瘤防治杂志,2022,29(5):337-344. [10] 张秀杰,张波,马璨粲.前列腺癌患者血浆miR-135、miR-103、miR-34b表达水平及其与临床病理特征和预后的关系[J].临床和实验医学杂志,2022,21(5):512-518. [11] Hanafi AR,Jayusman AM,Imelda P,et al.Correlation of serum electrolytes with serial miRNA in advanced stage non-small cell lung cancer (NSCLC) in Indonesia[J].BMC Res Notes,2021,14(1):437. [12] Garinet S,Didelot A,Denize T,et al.Clinical assessment of the miR-34,miR-200,ZEB1 and SNAIL EMT regulation hub underlines the differential prognostic value of EMT miRs to drive mesenchymal transition and prognosis in resected NSCLC[J].Br Cancer,2021,125(11):1544-1551.
2024, Vol. 30 
冀公网安备13080202000677号